Regulatory T cell– tag –
-
iPS Cells & Regenerative Medicine
Cellistic Expands iPSC Therapy Manufacturing with New GMP Platforms for Immuno-Oncology and Regenerative Medicine
Cellistic Press Release (via PharmaTimes) Belgium Overview Cellistic has introduced three new GMP manufacturing platforms—Echo-T, Echo-Cardio, and Echo-Endothelial—significantly expanding its capabilities for iPSC-derived cell therapies.... -
iPS Cells & Regenerative Medicine
FDA Approves Tregzi, First Regulatory T-Cell (Treg) Immunotherapy for Chronic GVHD Prevention, Expands Casgevy Indication to Pediatric Patients
Cell and Gene Therapy Catapult USA Overview On June 30, 2026, the U.S. FDA approved Tregzi, the first regulatory T-cell (Treg)-based immunotherapy designed to prevent chronic graft-versus-host disease (GVHD) and improve survival. Tregzi ... -
New Technology
Dual-Target CAR T Therapy for Glioblastoma Drives Broad Immune Activation, NK Cell Response Correlates with Long-Term Survival in Penn Medicine Study
Vertex AI Search USA Overview Researchers at the Perelman School of Medicine and Abramson Cancer Center discovered that direct intra-cerebrospinal fluid (CSF) delivery of a dual-target CAR T-cell therapy induces a broad immune response i...
1